Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies. [electronic resource]
Producer: 20180209Description: 1186-1192 p. digitalISSN:- 1557-3265
- Adult
- Aged
- Aged, 80 and over
- Aminopyridines -- administration & dosage
- B-Lymphocytes -- drug effects
- Benzamides -- administration & dosage
- Cyclic Nucleotide Phosphodiesterases, Type 4 -- drug effects
- Cyclopropanes -- administration & dosage
- Drug-Related Side Effects and Adverse Reactions -- pathology
- Female
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasms -- drug therapy
- Phosphatidylinositol 3-Kinases -- genetics
- Phosphodiesterase 4 Inhibitors -- administration & dosage
- Phosphoinositide-3 Kinase Inhibitors
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article
There are no comments on this title.
Log in to your account to post a comment.